In a major advancement for chemical research, Elsevier, a global leader in information and analytics, has announced a strategic partnership with Enamine, a world-renowned supplier of small molecules and early drug discovery services. This collaboration will see Enamine’s extensive database of over 43 million make-on-demand (MADE) analog compounds integrated into Elsevier’s flagship chemical database, Reaxys.
This integration aims to significantly speed up drug discovery and materials science research by giving chemists immediate access to a broader array of novel compounds. Reaxys, known for its comprehensive chemical data derived from scientific journals and patents, now leverages Enamine's synthesis expertise to streamline the Design-Make-Test-Analyze (DMTA) cycle for researchers.
Enamine boasts a success rate of over 70% for synthesizing novel MADE compounds, typically completing the synthesis process within two to six weeks. This efficiency can cut development times and costs by as much as 90%, offering a significant boost to pharmaceutical and materials R&D. The compounds are derived from Enamine’s MADE building blocks and REAL (REadily AccessibLe) screening compounds, synthesized from in-stock reagents in one to five well-validated steps.
Each compound in the Enamine database comes with detailed pricing and lead-time information, helping researchers make faster, data-driven decisions. The collaboration is further enhanced by Chemspace, a specialist in managing ultra-large chemical datasets, which will handle order processing for Enamine compounds.
The integration aligns with Reaxys’ mission to support innovation in drug discovery, chemical R&D, and academic research by offering over a billion chemistry data points combined with AI-driven insights. With access to Enamine’s expansive compound collection, Reaxys users can more efficiently identify potential drug targets, biomarkers, and screening compounds, accelerating the path to discovery.
Reaxys customers can access Enamine’s compound database immediately.
This partnership marks a significant step in the evolution of chemistry research, combining cutting-edge synthesis capabilities with state-of-the-art data analytics to drive innovation faster than ever before.
Click here to read the original press release.
